Introduction
Thyroid dysfunctions represent the commonest endocrine disorders in patients with Down syndrome (DS). Derangements in thyroid function in DS may present at any stage in life: congenitally, neonatally, in childhood or adulthood. An elevation in the thyroid-stimulating hormone (TSH) level or hyperthyrotropinemia (HT) is the most common thyroid disorder associated with Down’s syndrome. The spectrum of thyroid dysfunction in children with DS include congenital hypothyroidism, subclinical hypothyroidism (SH), overt hypothyroidism (OH). Adult DS patients with hypothyroid have a greater percentage of cases positive for anti-thyroid antibodies but the etiological basis for hyperthyrotropinemia in the pediatric age group remains obscure. While some authors have implicated an autoimmune pathology similar to Hashimoto’s thyroiditis others have suggested that a delayed maturation of the hypothalamo-pituitary-thyroid axis might be responsible. Their theories include an over-secretion of TSH due to hyper-responsiveness to interferons or an erroneous dopaminergic control of the pituitary gland. While it was postulated that a mild elevation in TSH or SH can eventually lead to OH, this theory has been challenged by subsequent findings that many of these cases only show a transient rise...
in TSH\[9\] and non-progression to OH, even on long-term follow up.\[10\] The implication of the elevation of TSH has also been questioned based on its lack of association with clinical symptoms.\[9\] From a therapeutic perspective, these add up to the vital question of the necessity of thyroid hormone replacement therapy in the pediatric DS patients with hyperthyrotropinemia, with some studies indicating effectiveness and others lack of any benefit of such treatment.\[11,12\]

Identification of features specific to the presentation and biochemical manifestations of hyperthyrotropinemia in children with DS is essential to better understand the etiological basis as well as deciding upon screening and treatment strategies. Median age at presentation, family history of thyroid disease, baseline TSH level, presence of goitre, thyroid antibody positivity were found to be important determinants of outcome in hypothyroidism with DS.\[13-18\] But there is very limited literature on Hypothyroidism in DS especially in children, accordingly, in the present study, we have investigated hypothyroid Indian children with and without DS (NDS), especially focusing on age at presentation, family history, goiter, and TPO antibody positivity.

The protocol was presented to the ethics committee of the KPC Medical College and Hospital. Given the retrospective nature of the study and collection of data from the electronic database, the ethics committee suggested that the formal approval process can be dispensed with.

**Materials and Methods**

We conducted this retrospective observational study from previous medical records of children with DS patients (1–17 years) having an elevated TSH (≥5 mIU/L) who were consecutively referred for HT to Endocrinology specialty OPD of a tertiary care hospital in India. Records from hypothyroid children (1–17 years) without Down Syndrome (NDS) were evaluated as controls. We mainly focused on age at presentation, sex, family history of thyroid disease, presence of goiter, baseline TSH and TPO antibody positivity status between DS and NDS with hyperthyrotropinemia. Congenital hypothyroidism was excluded in both arms, as also patients taking medications that can affect thyroid status, like amiodarone, lithium, interferons. Recorded data of Thyroid-stimulating hormone (TSH), Free thyroxine (FT4), anti-Thyroid peroxidase (TPO) antibody, were evaluated in the controls and tests. Serum FT4, TSH, and anti-TPO levels were measured by electrochemiluminescence immunoassay (Cobas e 411 Analyser, Roche Diagnostics, GMBH Mannheim). Reference ranges after one month of age were TSH 0.5–5.0 µU/ml and Free T4 0.9–1.7 ng/dl, while reference for anti-TPO antibody positivity was anti-TPO antibodies above 34 IU/ml. Based on thyroid function test results, participants were classified using the following definitions: overt hypothyroidism (OH) low serum FT4 (i.e., <0.9 ng/dl) and elevated TSH >10 µU/ml; For subclinical hypothyroidism (SH), we considered a normal serum FT4 (0.9–1.7 ng/dl) along with elevated TSH ≥5 mIU/L.

Kolmogorov-Smirnov test was used to test the normality of the data. Comparisons between groups were performed by unpaired Student’s t-test for continuous data and Fischer’s exact test for categorical data. A P value < 0.05 was considered to be statistically significant. All analyses were performed on SPSS Version 16.0.1 (SPSS Inc., Chicago, 2007).

**Results**

A total of 34 hypothyroid patients with DS and 34 with NDS were included. The characteristics of the hypothyroid study subjects with and without DS are tabulated [Table 1]. The groups were comparable in terms of age and gender. Hypothyroid subjects with DS had a significantly less positive family history of thyroid disorders compared to NDS children and goiter was significantly less common in hypothyroid children with DS compared to NDS. The rates of positivity of anti-TPO antibody significantly less in DS children with HT compared to NDS [Supplementary Table 1].

The characteristics of anti-TPO negative (n = 20) and anti-TPO positive (n = 14) subjects with and without DS are tabulated [Supplementary Table 1]. The anti-TPO negative group had earlier median age of presentation, but no significant difference in traceable family history and presence of goiter were seen. OH was significantly more common in TPO positive DS children, conversely SH was more common in TPO negative DS children.

**Discussion**

A link between DS and hyperthyrotropinemia has been long documented.\[9\] Thyroid dysfunction is the commonest endocrine disorders in DS, with elevated TSH level or HT being the commonest thyroid disorder in DS.\[11,12\] Identification of features related to presentation and biochemical manifestations of hypothyroidism in children with DS may help in deciding upon screening, treatment, and follow-up strategies. In our study, hypothyroid children with DS compared to NDS had 1 significantly earlier median age of presentation, lower incidence of traceable family history of thyroid disorders. In the present study, hypothyroid children with and without DS were comparable in terms of gender, Goiter was significantly less common in hypothyroid children with DS compared to NDS. The rates of positivity of anti-TPO antibody were significantly lower in hypothyroid children with DS compared to NDS. TPO positive DS children had significantly more OH, conversely SH was more common in TPO negative DS children.

Thyroid dysfunction in DS may present at any stage in life.\[11\] In a retrospective records review by Pierce et al., thyroid disease in DS was more common and occurred earlier than in the general population, but was often transient and was unrelated to gender, obesity, or other comorbidities.\[13\] HT in DS is associated with a lack of clinical features.\[9\] Amr reported that the main features of autoimmune hypothyroidism in DS versus the general population were equal sex distribution, earlier age of onset, lower antibody titer at diagnosis, lower rate of positive family history, and higher rate of progression to overt disease.\[15\]
Table 1: Characteristics of the study participants

| Parameter                             | Children with hyperthyrotropinemia with Down’s Syndrome (n = 34) | Children with hyperthyrotropinemia without Down’s Syndrome (n = 34) | P value |
|---------------------------------------|---------------------------------------------------------------|-------------------------------------------------------------------|--------|
| Median age, IQR (in years)            | 8.00 (2.00-14.00)                                             | 10.50 (7.13-25)                                                  | 0.181  |
| Median age at presentation, IQR (in years) | 7.00 (1.00-11.00)                              | 10.00 (5.75-13.25)                                               | 0.010  |
| Sex (% female)                        | 61.76                                                        | 61.76                                                            | 1.000  |
| Family history (% present)            | 14.70                                                        | 64.70                                                            | <0.0001|
| Thyroid status (% subclinical)        | 41.17                                                        | 52.94                                                            | 0.466  |
| Median TSH, IQR                       | 13.00 (7.80-22.47)                                            | 9.62 (8.00-40.58)                                                | 0.735  |
| Median FT4, IQR                       | 1.03 (0.75-1.308)                                             | 0.92 (0.65-1.24)                                                 | 0.643  |
| Median Anti-TPO, IQR                  | 30.00 (16.43-89.50)                                           | 89.00 (34.00-120.00)                                             | 0.005  |
| Goiter (% present)                    | 41.17                                                        | 73.52                                                            | 0.014  |

King et al. reported anti-TPO antibody positivity of 7.5–31% in DS children, but not exclusively with hyperthyrotropinemia.[7] Adult DS patients with hypothyroid have a greater percentage of cases positive for anti-thyroid antibodies.[3] Pierce et al., reported a higher likelihood of antibody positivity in DS with higher TSH levels.[10] We found significantly lower (41%) anti-TPO positivity in hypothyroid children with DS compared to NDS (73.5%) children. The autoantibody positivity rate in the NDS group mirrors previous data and can thus be considered representative.[18-20] Some reports suggest that autoantibodies appear in DS patients only after the age of 5 years or 8 years while other authors have reported detectable autoantibody levels even at infancy.[21] In our cohort, antibody levels in DS patients were detected as early as 2 years of age. A recent 5-year prospective multicenter study in 101 DS subjects, aged 2–17 years, reported a higher risk of thyroid function deterioration over time was influenced by thyroid autoimmunity and higher baseline TSH.[14]

In our study, hypothyroid children with DS had earlier presentation and lower rates of goiter, these are apparently contradictory as greater duration of exposure to an elevated TSH level could lead to a greater degree of goiter. However, goiter and OH were significantly more frequent in our DS children with elevated anti-TPO antibodies, whereas DS children with low anti-TPO antibodies had more SH. While overlaps are possible, as is also apparent in our cohort, such a distinction might be helpful in planning therapeutic interventions, follow-up schedules, and prognostication.

Limitations of the study were its retrospective nature, relatively small sample, nonrandom sampling, and differential detection due to bias for hypothyroidism in DS versus NDS, because of well-known risk of hypothyroidism in DS. Several clinical parameters like growth and developmental parameters were not documented. Longitudinal data including treatment outcomes were not assessed due to poor follow-up.

**Conclusion**

**In conclusion**, there is a significant difference in presentation in hypothyroid children with DS compared to NDS. In our study, hypothyroid children with DS compared to NDS, had an earlier age at presentation, but lower incidence of traceable family history of thyroid disease, anti TPO-antibody positivity and goiter.

**Financial support and sponsorship**

Nil.

**Conflicts of interest**

There are no conflicts of interest.

**References**

1. Graber E, Chacko E, Regelmann MO, Costin G, Rapaport R. Down syndrome and thyroid function. Endocrinol Metab Clin North Am 2012;41:735-45.
2. Meyerovitch J, Antebi F, Greenberg-Dotan S, Bar-Tal O, Hochberg Z. Hyperthyrotropinemia in untreated subjects with Down’s syndrome aged 6 months to 64 years: A comparative analysis. Arch Dis Child 2012;97:595-8.
3. Karlsson B, Gustafsson J, Hedov G, Ivansson SA, Annerén G. Thyroid dysfunction in Down’s syndrome: Relation to age and thyroid autoimmunity. Arch Dis Child 1998;79:242-5.
4. Rubello D, Pozzan GB, Casara D, Girelli ME, Boccati S, Rigon F, et al. Natural course of subclinical hypothyroidism in Down’s syndrome: Prospective study results and therapeutic considerations. J Endocrinol Invest 1995;18:35-40.
5. Prasher VP. Down syndrome and thyroid disorders: A review. Downs Syndr Res Pract 1999;6:25-42.
6. Tüysüz B, Beker DB. Thyroid dysfunction in children with Down’s syndrome. Acta Paediatr 2001;90:1389-93.
7. King K, O’Gorman C, Gallagher S. Thyroid dysfunction in children with Down syndrome: A literature review. Ir J Med Sci 2014;183:1-6.
8. Cutler AT, Benezza-Obeiter R, Brink SI. Thyroid function in young children with Down syndrome. Am J Dis Child 1986;140:479-83.
9. Gibson PA, Newton RW, Selby K, Price DA, Leyland K, Addison GM. Longitudinal study of thyroid function in Down’s syndrome in the first two decades. Arch Dis Child 2005;90:574-8.
10. Faria CD, Ribeiro S, Kochi C, Silva AP, Ribeiro BN, Marçal LT, et al. TSH neurosecretory dysfunction (TSH-nd) in Down syndrome (DS): Low risk of progression to Hashimoto’s thyroiditis. Arq Bras Endocrinol Metabol 2011;55:628-31.
11. van Trotsenburg AS, Vulsma T, van Rozenburg-Marres SL, van Baar AL,
Ridder JC, Heymans HS, et al. The effect of thyroxine treatment started in the neonatal period on development and growth of two-year-old Down syndrome children: A randomized clinical trial. J Clin Endocrinol Metab 2005;90:3304-11.

12. Tirosh E, Taub Y, Scher A, Jaffe M, Hochberg Z. Short-term efficacy of thyroid hormone supplementation for patients with Down syndrome and low-borderline thyroid function. Am J Ment Retard 1989;93:652-6.

13. Pierce MJ, LaFranchi SH, Pinter JD. Characterization of thyroid abnormalities in a large cohort of children with Down syndrome. Horm Res Paediatr 2017;87:170-8.

14. Pepe G, Corica D, De Sanctis L, Salerno M, Faienza MF, Tessaris D, et al. Thyroid Study Group of the Italian Society of Pediatric Endocrinology and Diabetology (ISPED). Prospective evaluation of autoimmune and non-autoimmune subclinical hypothyroidism in Down syndrome children. Eur J Endocrinol 2020;182:385-92.

15. Amr NH. Thyroid disorders in subjects with Down syndrome: An update. Acta Biomed 2018;89:132-9.

16. Crisafulli G, Aversa T, Zirilli G, Pajno GB, Corica D, De Luca F, et al. Subclinical hypothyroidism in children: When a replacement hormonal treatment might be advisable. Front Endocrinol (Lausanne) 2019;10:109.

17. Claret C, Goday A, Benajes D, Chillarón JJ, Flores JA, Hernandez E, et al. Subclinical hypothyroidism in the first years of life in patients with Down syndrome. Pediatr Res 2013;73:674-8.

18. Ghoraishian SM, Hekmati Moghaddam SH, Afkhami-Ardekani M. Relationship between anti-thyroid peroxidase antibody and thyroid function test. Iran J Immunol 2006;3:146-9.

19. Gayathri R, Lavanya S, Raghavan K. Subclinical hypothyroidism and autoimmune thyroiditis in pregnancy-A study in south Indian subjects. J Assoc Physicians India 2009;57:691-3.

20. Mohanty S, Amruthlal W, Reddy GC, Kusumanjali G, Kanagasabapathy AS, Rao P. Diagnostic strategies for subclinical hypothyroidism. Indian J Clin Biochem 2008;23:279-82.

21. Pascaru I, Banescu C, Benedek T, Duici C, Csep K, Dema A. Thyroid dysfunction in children with Down’s syndrome. Acta Endocrinol (Bucharest, Rom.) 2009;5:85-92.
### Supplementary Table 1: Comparison between TPO positive and TPO negative study subjects

|                                | Anti-TPO negative | Anti-TPO positive | P value | P value |
|--------------------------------|-------------------|-------------------|---------|---------|
|                                | DS (n = 20)       | NDS (n = 9)       |         |         |
| Median age at presentation (years) | 7.5               | 8                 | 0.978   |         |
| Presence of family history (%)  | 20.00             | 77.77             | 0.010   |         |
| Presence of goiter (%)          | 5.00              | 44.44             | 0.022   |         |
| TSH levels                      | 8.27              | 9.00              | 0.220   |         |
|                                | DS (n = 14)       | NDS (n = 25)      |         |         |
| Median age at presentation (years) | 3                 | 11                | 0.0005  |         |
| Presence of family history (%)  | 28.57             | 72.00             | 0.017   |         |
| Presence of goiter (%)          | 50.00             | 72.00             | 0.297   |         |
| TSH levels                      | 21.61             | 11.60             | 0.291   |         |